BioSpace News Archive

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”) today announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated, randomized, placebo-controlled Phase I/II trial to evaluate the efficacy, safety and tolerability of Allocetra™ following injection into patients with basal thumb joint (first carpometacarpal (CMC) joint) osteoarthritis.

Arcutis Biotherapeutics, Inc. today announced that Arcutis management will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, taking place June 10-13, 2024.

Cue Biopharma, Inc. today announced that it will participate in two investor conferences this June, the Jefferies Global Healthcare Conference, to be held in New York, NY, June 4-6 and the Oppenheimer Novel Targets and Immunology Summit, to be held in New York, NY on June 24.

aTyr Pharma, Inc. announced that the Company will be changing its ticker symbol from “LIFE” to “ATYR.” Effective at the market open on June 5, 2024, the Company’s common stock will trade on the Nasdaq Capital Market under the new symbol “ATYR.”

Aquestive Therapeutics, Inc. today announced it has strengthened its leadership team with three executive appointments ahead of the anticipated launch of Anaphylm™.

Denali Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program.

Summit Therapeutics Inc. announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million.

Diakonos Oncology Corp., a clinical-stage immuno-oncology company, announced that Chief Financial Officer and Head Of Business Development Anthony Baldor will give a company presentation at the 2024 BIO International Convention June 3 – 6, 2024 in San Diego.

RadNet, Inc. announced that Dr. Howard Berger, President and Chief Executive Officer, will be presenting at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024 at 11:30 a.m. Eastern Time.

Bio-Thera Solutions Inc., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for Avzivi®, a biosimilar monoclonal antibody referencing AVASTIN®.